全国服务咨询热线：
18438616290
18438616290
产品分类
Product Category详细介绍
| 品牌 | absin | CAS | 152121-47-6 |
|---|---|---|---|
| 分子式 | C21H16FN3OS | 纯度 | ＞98% |
| 分子量 | 377.44 | 货号 | abs810002 |
| 规格 | 5mg;10mg;100mg | 供货周期 | 现货 |
| 主要用途 | - | 应用领域 | 化工,生物产业,农林牧渔,制药/生物制药,综合 |
| 产品描述 | |
| 描述 | SB 203580是一种p38 MAPK抑制剂，在THP-1细胞中IC50为0.3-0.5μM，对SAPK3(106T)和SAPK4(106T)选择性低10倍，且阻断PKB磷酸化，IC50为3-5μM。SB203580是第一个被报道的p38抑制剂。 |
| 纯度 | ＞98% |
| 储存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 别名 | Adezmapimod；RWJ 64809 |
| 外观 | white to off-white powder |
| 可溶性/溶解性 | DMSO：43 mg/mL (113.92 mM) |
| 生物活性 | |
| 靶点 | p38 MAPK；PKB |
| In vitro(体外研究) | SB 203580 inhibits the IL-2-induced proliferation of primary human T cells, murine CT6 T cells, or BAF F7 B cells with an IC50 of 3–5 μm. SB203580 also inhibits IL-2-induced p70S6 kinase activation, although the concentration required is slightly higher with an IC50 above 10 μm. SB203580 also inhibits the activity of PDK1 in a dose-dependent manner with an IC50 in the 3–10 μm range. SB203580 inhibits p38-MAPK stimulation of MAPKAPK2 with an IC50 of approximately 0.07 μM, whereas inhibits total SAPK/JNK activity with an IC50 of 3–10 μM. SB203580 at higher concentrations activates the ERK pathway, which subsequently enhances NF-κB transcriptional activity. SB203580 induces autophagy in human hepatocellular carcinoma (HCC) cells. |
| In vivo(体内研究) | SB203580 protects pig myocardium against ischemic injury in an in vivo model. SB203580 is effective to prevent and treat the disease in MRL/lpr mice model of Systemic lupus erythematosus (SLE). |
| 研究领域 | |
| 研究领域 | ImmunologyInnate ImmunityTLR Signaling NeuroscienceDevelopment NeuroscienceProcesses Signal TransductionProtein PhosphorylationSer / Thr KinasesMAPK Pathway Drug DiscoverySmall Molecule DrugLead Compound Discovery |
产品咨询
地址：上海市浦东新区新浩路58号申江科创园18栋
邮箱：lanwu@univ-bio.com
传真：